|
Jul 20
|
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
|
|
Jul 19
|
The past five years for Sangamo Therapeutics (NASDAQ:SGMO) investors has not been profitable
|
|
Jul 17
|
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
|